Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022GlobeNewsWire • 04/25/22
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 04/06/22
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/16/22
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®GlobeNewsWire • 03/11/22
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 03/09/22
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small CompaniesGlobeNewsWire • 03/08/22
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022GlobeNewsWire • 03/03/22
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging IndustryZacks Investment Research • 03/02/22
Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should KnowZacks Investment Research • 02/28/22
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022GlobeNewsWire • 02/24/22
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022GlobeNewsWire • 02/17/22
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?Zacks Investment Research • 02/10/22
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare ActivityBenzinga • 02/07/22
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate UpdateGlobeNewsWire • 02/07/22
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer ValidGlobeNewsWire • 02/03/22